CBIO | Catalyst Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.4800 - 0.5796
52 Week Range	0.1887 - 8.69
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	460,710
Average Volume	437,269
Shares Outstanding	37,978,100
Market Cap	19,418,203
Sector	Healthcare
Industry	Biotechnology
IPO Date	2006-04-12

Valuation
Profitability
Growth
Health
P/E Ratio	-0.02
Forward P/E Ratio	-7.76
EPS	-20.70
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	7
Country	USA
Website	CBIO

Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.

CBIO's peers: ADIL, ALRN, APRE, BNTC, BPTH, CAPR, CASI, CLRB, COCP, CYCC, DARE, MBRX, MRKR, MTEM, PULM, RNXT, SLNO, TPST, VYNE, XCUR, IMNN, LSTA, TOVX

*Chart delayed

Analyzing fundamentals for CBIO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CBIO Fundamentals page.

Watching at CBIO technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on CBIO Technicals page.